BTAI insider transactions
BioXcel Therapeutics Inc. (BTAI) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for BTAI
- Chief Scientific Officer Yocca Frank converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,175 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Officer Rodriguez Javier converted options into 17,500 shares and sold $7,111 worth of shares (6,560 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,803 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Financial Officer Steinhart Richard I converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 68% to 26,300 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- CEO and President Mehta Vimal converted options into 49,758 shares and sold $21,108 worth of shares (19,419 units at $1.09) as part of a pre-agreed trading plan, increasing direct ownership by 77% to 69,598 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- CEO and President Mehta Vimal converted options into 18,000 shares, increasing direct ownership by 85% to 39,259 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Financial Officer Steinhart Richard I converted options into 9,000 shares, increasing direct ownership by 135% to 15,645 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Scientific Officer Yocca Frank converted options into 9,000 shares, increasing direct ownership by 138% to 15,520 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Officer Rodriguez Javier converted options into 9,000 shares, increasing direct ownership by 131% to 15,863 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- CEO and President Mehta Vimal converted options into 383 shares, increasing direct ownership by 2% to 21,259 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Financial Officer Steinhart Richard I converted options into 68 shares, increasing direct ownership by 1% to 6,645 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Officer Rodriguez Javier converted options into 68 shares, increasing direct ownership by 1% to 6,863 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Scientific Officer Yocca Frank converted options into 68 shares, increasing direct ownership by 1% to 6,520 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Director Laumas Sandeep4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Director Patni Rajiv4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Director Mueller Peter4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Director Votruba Michal4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Director Miller Michael Patrick4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Director Bray June4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Director Mack David J.4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Yocca Frank4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Steinhart Richard I4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by CEO and President Mehta Vimal4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Officer Rodriguez Javier4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- CEO and President Mehta Vimal converted options into 383 shares, increasing direct ownership by 2% to 20,876 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Financial Officer Steinhart Richard I converted options into 68 shares, increasing direct ownership by 1% to 6,577 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Officer Rodriguez Javier converted options into 68 shares, increasing direct ownership by 1% to 6,795 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Scientific Officer Yocca Frank converted options into 68 shares, increasing direct ownership by 1% to 6,452 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Director Mack David J. converted options into 1,694 shares, increasing direct ownership by 9% to 20,317 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Director Mack David J. converted options into 1,694 shares, increasing direct ownership by 10% to 18,623 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- CEO and President Mehta Vimal converted options into 382 shares, increasing direct ownership by 2% to 20,493 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Financial Officer Steinhart Richard I converted options into 68 shares, increasing direct ownership by 1% to 6,509 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Officer Rodriguez Javier converted options into 68 shares, increasing direct ownership by 1% to 6,727 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Scientific Officer Yocca Frank converted options into 68 shares, increasing direct ownership by 1% to 6,384 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 11% to 16,930 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Steinhart Richard I4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Officer Rodriguez Javier4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Yocca Frank4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by CEO and President Mehta Vimal4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 12% to 15,237 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- CEO and President Mehta Vimal was granted 15,625 shares, increasing direct ownership by 348% to 20,111 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Scientific Officer Yocca Frank was granted 4,375 shares, increasing direct ownership by 225% to 6,316 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Financial Officer Steinhart Richard I was granted 4,375 shares and converted options into 625 shares, increasing direct ownership by 347% to 6,441 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Officer Rodriguez Javier was granted 4,375 shares and converted options into 625 shares, increasing direct ownership by 301% to 6,659 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 14% to 13,544 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Financial Officer Steinhart Richard I converted options into 68 shares, increasing direct ownership by 5% to 1,441 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Scientific Officer Yocca Frank converted options into 68 shares, increasing direct ownership by 4% to 1,941 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- CEO and President Mehta Vimal converted options into 382 shares, increasing direct ownership by 9% to 4,486 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Officer Rodriguez Javier converted options into 68 shares, increasing direct ownership by 4% to 1,659 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 17% to 11,851 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 20% to 10,158 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by O'Neill Vincent4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by CEO and President Mehta Vimal4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Steinhart Richard I4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Wiley Matthew T.4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Officer Rodriguez Javier4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Yocca Frank4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Director Mack David J. converted options into 1,693 shares, increasing direct ownership by 25% to 8,465 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Financial Officer Steinhart Richard I converted options into 65 shares, increasing direct ownership by 5% to 1,373 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Officer Rodriguez Javier converted options into 65 shares, increasing direct ownership by 4% to 1,591 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- Chief Scientific Officer Yocca Frank converted options into 65 shares, increasing direct ownership by 4% to 1,873 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)